Alpha 2.0
Login Register
» Authors » D Kowalski

D Kowalski

Explore the profile of D Kowalski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 98
Citations 1332
Followers 0
Related Specialties
General Medicine
Biochemistry
Oncology
Top 10 Co-Authors
K Kowalska
J Starzyk
E Banasinska
J Przybylowski
A Zagala
S Gozdz
J Sluszniak
R M Umek
W Korejba
J Bukowski
Published In
Wiad Lek
Pol Tyg Lek
Nucleic Acids Res
Biochemistry
Pol Arch Med Wewn
Affiliations
Soon will be listed here.
Recent Articles
1.
Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial
Camerini A, Morabito A, Montanino A, Bernabe R, Grossi F, Ramlau R, et al.
ESMO Open . 2021 Feb; 6(2):100051. PMID: 33611164
Background: To assess the efficacy and safety of a metronomic schedule of oral vinorelbine (mVNR) in advanced non-small-cell lung cancer (NSCLC) in patients unfit for platinum-based combination chemotherapy. Patients And...
2.
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
Planchard D, Reinmuth N, Orlov S, Fischer J, Sugawara S, Mandziuk S, et al.
Ann Oncol . 2020 Mar; 31(5):609-618. PMID: 32201234
Background: Many patients with metastatic non-small-cell lung cancer (mNSCLC) experience disease progression after first- and second-line treatment; more treatment options are required for these patients. ARCTIC, a phase III, randomized,...
3.
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy
Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, et al.
Ann Oncol . 2018 May; 29(7):1535-1540. PMID: 29722791
Background: NEPA, an oral fixed combination of the NK1RA netupitant (300 mg) and clinically/pharmacologically distinct 5-HT3RA palonosetron (PALO, 0.50 mg), is the first fixed antiemetic combination to have been approved....
4.
QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization
Keirns J, Desai A, Kowalski D, Lademacher C, Mujais S, Parker B, et al.
Clin Pharmacol Ther . 2017 Jan; 101(6):782-790. PMID: 28074556
The effects of isavuconazole (active moiety of isavuconazonium sulfate) on cardiac ion channels in vitro and cardiac repolarization clinically were assessed in a phase I, randomized, double-blind study in healthy...
5.
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer
Krzakowski M, Bennouna J, Dansin E, Kowalski D, Hiret S, Penel N, et al.
Cancer Chemother Pharmacol . 2013 Nov; 73(2):231-6. PMID: 24220936
Background: Erlotinib, the epidermal growth factor receptor tyrosine kinase inhibitor, and the intra-venous vinflunine vinca alkaloid microtubule inhibitor have been shown to be effective in the setting of non-small-cell lung...
6.
A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects
Goldwater R, Keirns J, Blahunka P, First R, Sawamoto T, Zhang W, et al.
Am J Transplant . 2013 Jan; 13(4):1040-1046. PMID: 23356210
This first-in-human, phase I study evaluated the safety, tolerability, pharmacokinetic and pharmacodynamic profile of ASKP1240 in healthy subjects. Twelve sequential groups (each 6 active and 3 placebo) were randomly assigned...
7.
Prediction of pouch of Douglas obliteration in women with suspected endometriosis using a new real-time dynamic transvaginal ultrasound technique: the sliding sign
Reid S, Lu C, Casikar I, Reid G, Abbott J, Cario G, et al.
Ultrasound Obstet Gynecol . 2012 Sep; 41(6):685-91. PMID: 23001892
Objective: To evaluate preoperative real-time dynamic transvaginal sonography (TVS) in the prediction of pouch of Douglas (POD) obliteration in women undergoing laparoscopy for suspected endometriosis. Methods: This was a multicenter...
8.
Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression
Psyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Diamandis E, et al.
Ann Oncol . 2008 Mar; 19(7):1271-1277. PMID: 18325919
Background: Kallikreins, a subgroup of the serine protease enzyme family, are considered important prognostic biomarkers in cancer. Here, we sought to determine the prognostic value of kallikrein 7 (hk7) in...
9.
Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with beta-catenin levels and outcome in patients with epithelial ovarian cancer
Bamias A, Yu Z, Weinberger P, Markakis S, Kowalski D, Camp R, et al.
Ann Oncol . 2006 Sep; 17(12):1797-802. PMID: 16971669
Background: The deleted in colorectal cancer (DCC) protein, the product of DCC tumor suppressor gene, is frequently altered in cancer. Preclinical data demonstrate that DCC regulates beta-catenin levels. Here, we...
10.
Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer
Weinberger P, Yu Z, Haffty B, Kowalski D, Harigopal M, Sasaki C, et al.
Clin Cancer Res . 2004 Sep; 10(17):5684-91. PMID: 15355894
Purpose: Functional inactivation of p16 is an early and frequent event in head and neck squamous cell cancers. In this study, we sought to determine whether p16 expression is of...